Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209 · clinicaltrials.gov ↗

COMPLETED

Status

331541

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration (AMD)

Interventions

OTHER: Aflibercept
OTHER: Ranibizumab
OTHER: Bevacizumab

Sponsor

Novartis Pharmaceuticals